IBT Examines Strategies Aimed At Promoting Antibiotic Drug Development

International Business Times: Antibiotic Resistance: Why Aren’t Drug Companies Developing New Medicines To Stop Superbugs?
“…[A]s many as 10 million people a year could die from antibiotic-resistant bacteria worldwide by 2050 if new treatments are not discovered, according to a recent report from the Review on Antimicrobial Resistance. … Despite that urgency, most of the world’s largest pharmaceutical companies stopped making antibiotics long ago, citing high costs of development and low returns. … Therefore, only a fraction of the medicines that are needed are being produced…” (Nordrum, 3/3).